Satellite Symposia
The Satellite Symposia are industry-sponsored programs offered in conjunction with ASH specialty meetings. These events are offered in conjunction with the 2024 Highlights of ASH in Latin America and are not part of the official ASH meeting programming and are planned solely by the sponsoring company. There is no fee to attend and registration to HOA is not required to participate.
The 2024 Satellite Symposia are each presented in-person, once, live at the date, time, and location listed. To register, click the “Register” button below each title in the schedule. Check back as registration links and details will continue to be added as managing companies share them with ASH. For program-specific questions, please reach out to the managing company contact listed below each session.
Satellite Symposia are Open to All Attendees Free of Charge. No registration is Required.
ASTELLAS
AML R/R Disease Evolution, Approach Post ASH Data
APRIL 19, 2024, 5:00 P.M. TO 5:45 P.M
PLAZA MAYOR CONVENTION CENTER – COMISION 1 + 2 MEETING ROOM
The symposium will discuss the current approach and treatment of AML R/R, with particular focus on patients with FLT3 biomarker, following an update from the ASH congress.
SPEAKER: DR. PAOLA OMAŇA, HEMATOLOGIST, Cancer Treatment and Research Center Luis Carlos Sarmiento Angulo (CTIC)
CHAIRPERSON: DR. CLAUDIA AGUDELO, HEMATOLOGIST, National University of Colombia
Santa Fe de Bogotá Foundation
JANSSEN
The Art of Deepening Responses and Clinical Outcomes in Multiple Myeloma
APRIL 19TH, 2024, 5:00 P.M. TO 5:45 P.M.
PLAZA MAYOR CONVENTION CENTER – COMISION 7+8+9 MEETING ROOM
The symposium about deepening responses and clinical outcomes in Multiple Myeloma aims to instruct the hematologist about the importance of achieving in-depth responses on patients with multiple myeloma that are transplant eligible. In Colombia we don’t have a consensus that states in which moment patients should be transplanted and this practice varies among HCP´s and institutions. Some consider complete response, very good partial responses and other partial responses.
SPEAKER: DR. RAFAEL FONSECA, Clinical Hematology and Medical Oncology, Mayo Clinic College of medicine, Internal Medicine, University of Miami, Director of innovation and transformational relationships Mayo Clinic campus of Arizona
NOVARTIS
Addressing Challenges: Key Advances in CML
APRIL 19TH, 2024, 5:00 P.M. TO 5:45 P.M.
PLAZA MAYOR CONVENTION CENTER – COMISION 3+4 MEETING ROOM
SPEAKERS: DR. JAVIER PINILLA-IBARZ, Hematologist, MD, PhD, Moffitt Cancer Center Magnolia, Tampa, FL
Dr. Pinilla-Ibarz has been at Moffitt since 2006 and holds the rank of Senior Member and Head of Lymphoma Section in the Department of Malignant Hematology. Dr. Pinilla-Ibarz received the 2016-17 Moffitt Physician of the Year Award. He was also the recipient of the ASCO young investigator award in 2003 and the ASCO career development award in 2007. Dr. Pinilla-Ibarz is nationally and internationally known for his expertise in chronic leukemia, and he currently has over 120 peer-reviewed publications. He has received grant support through the Leukemia & Lymphoma Society and from multiple industry partners. His clinical interests include chronic myeloid leukemia and chronic lymphoid leukemia. Dr. Pinilla-Ibarz's laboratory is interested in implementing new immunotherapeutic strategies in the field of malignant hematology. He has received grant support through Leukemia and Lymphoma Society, NIH/NCI, Bank Head Cooley and from multiple industry partners.
ALEXION-ASTRA ZENECA
ELEVATE-TN Update 6 years of Follow-up
APRIL 19TH, 2024, 6:00 P.M. TO 6:45 P.M.
PLAZA MAYOR CONVENTION CENTER – COMISION 1+2 MEETING ROOM
SPEAKERS: Dr. LUIS ANTONIO SALAZER MONTAÑA, Hematologist, Internal Medicine specialist. Colombian School of Medicine, Universidad el Bosque. Bogotá, Colombia. Hematology Specialist. Fundación Universitaria de Ciencias de La Salud- Hospital de San Jose. Bogotá, Colombia. Master in Hematopoietic Transplantation. Universidad de Valencia, Spain. Master in manufacturing of advanced therapeutic medicinal products. Universidad de Granada, Spain.
Current position: Hematologist in the Program for the Treatment of Hemato-Oncological Diseases of Santander- PROTEHOS LTDA.
Dr. Salazar has an extensive professional career in the clinical practice of hematology and has participated as a researcher and author in various research projects national and international publications aimed at hematological pathologies. Additionally, he has an outstanding academic career as an associate professor at the Universidad Autónoma de Bucaramanga and is a member of a research group recognized by the Minciencias and Scientific Societies: PETEMA, ACHO, EHA, GRIMMCO and EBMT. AND DR. MAURICIO ALZATE, Hematologist, specialist in Internal Medicine and Hematology. Hematologist at San Vicente Fundación Hospital. Dr Alzate has extensive experience in managing multiple hematologic pathologies, both benign and malignant.
BRISTOL MYERS SQUIBB
Controversies in the Treatment of Low-Risk MDS
APRIL 19TH, 2024, 6:00 P.M. TO 6:45 P.M.
PLAZA MAYOR CONVENTION CENTER – COMISION 3+4 MEETING ROOM
SPEAKER: DR. DAVID VALCÁRCEL, Hematologist, Associate professor at the Autonomous University of Barcelona - Spain, currently directs the Myeloid Pathology Research Group in the Experimental Hematology Group of the Vall Hebron Oncology Institute-Vall d'Hebron Hospital
CHAIRPERSON: DR. JHEREMY REYES, Healthcare hematologist at Clínica Cobos and Clínica Nogales, Professor at El Bosque University, Colombia
TAKEDA
Challenges in the Management of Patients with CHL: Update on the Therapeutic Approach
APRIL 19TH, 2024, 6:00 P.M. TO 6:45 P.M.
PLAZA MAYOR CONVENTION CENTER – COMISION 7+8+9 MEETING ROOM
SPEAKERS: DR. GUILLERMO QUINTERO, Hematologist, Santa Fe de Bogotá Foundation, University of the Andes Hematology and Cardiology Medical Services SAS, Bogota Colombia AND DR. KENNY GALVEZ, Hematologist, Hospital Pablo Tobón Uribe, Medellín, Colombia
Abbott
Rational Use of G-CSF: How, When and Where
APRIL 19TH, 2024, 7:30 P.M. TO 9:00 P.M.
INTERCONTINENTAL HOTEL – ANTIOQUIA 1 MEETING ROOM
Given the importance of G-CSF as a supportive care therapy in cancer patients who receive myelosuppressive chemotherapy, this lecture will reinforce aspects related to rational use of Pegfilgrastim, guideline updates, and remark How, When, and Where is the correct use.
SPEAKER: Dr. Miguel Sanz
Miguel Ángel Sanz Alonso is an Emeritus Researcher at La Fe Health Research Institute, Professor and Honorary Professor of the Department of Medicine at the University of Valencia. After obtaining his medical degree from the University of Salamanca in 1971 and his doctorate from the University of Valencia in 1977, he was an intern and resident physician in the Hematology Service at La Fe University Hospital. He was appointed Head of the Section of Clinical Hematology at the La Fe University Hospital in 1977 and later Head of the Hematology Service in 2006, as well as Full Professor and later Professor at the University of Valencia. Professor Sanz has been president of the Spanish Hematopoietic Transplant Group (GETH), is president of the PETHEMA Group and coordinates the acute myeloid leukemia working group. He is currently a reviewer for numerous high-profile medical journals, including all major hematology and oncology journals, and has authored more than 650 articles (hindex = 77), more than 110 book chapters, and more than 1,100 meeting papers. National and international. Professor Sanz is a full academician of the Royal Academy of Medicine of the Valencian Community and has given numerous conferences in Europe, North America, Central America, and South America, as well as in the Middle East and Asia, being a guest professor in numerous educational programs of the American Society of Hematology, the European Hematology Association and the European Blood and Marrow Transplantation among other prestigious medical societies.